An Update from Our Firm about COVID-19

Abraham, Watkins, Nichols, Sorrels, Agosto, Aziz & Stogner remains fully operational and committed to serving our clients and colleagues throughout the Coronavirus (COVID-19) crisis. As we follow the CDC guidelines and practice social distancing, we remain available for phone consultations and scheduled in-person meetings with both current and prospective clients and colleagues. Please contact our office by email or by calling 713-222-7211 with any questions. We look forward to hearing from you.

New data suggests increased risk of Topamax related birth defects

The Food and Drug Administration is warning women of child-bearing age that taking the drug Topamax has been associated with a higher rate of cleft lip and cleft palate in their newborn infants.

The warning is based on data showing that the birth defects occurred in 1.4 percent of infants that had prenatal exposure to the drug during the first trimester. This is about three times the rate of similar defects in infants whose mother had taken alternative anti-seizure medications. The rate of oral cleft defects when not taking any anti-seizure medication is only .07 percent.

Topamax is the brand name under which Johnson & Johnson sells the drug topiramate. It is also sold in generic form by a number of companies. The drug is approved as treatment for epileptic seizures and is also used to prevent migraines.

Topamax had previously been designated as a Category C drug, which indicates that animal studies have indicated a fetal risk. The FDA will now change Topamax to a Category D drug based on new data on the prevalence of oral cleft defects in humans. The drug will also be required to have a stronger warning on the label.

The FDA urges women who may become pregnant to discuss other treatment options with their health care professional and that women taking Topamax should inform their doctor immediately if they are planning a pregnancy.

Oral cleft defects occur when the palate or lips of a fetus do not correctly fuse together during the first month of pregnancy. Surgery is often required to repair the resulting gap in the mouth, palate or nose.

Source: U.S. Food and Drug Administration "FDA Drug Safety Communication: Risk of oral clefts in children born to mothers taking Topamax (topiramate)" March 4, 2011

No Comments

Leave a comment
Comment Information
  • $50+ Million Fire & Explosion

    The firm successfully represented nearly 100 victims who suffered personal injuries and damages to property from a large fire and explosion resulting in a settlement of more than $50 million. The firm served as lead lawyers on the steering committee in this litigation.

  • $80 Million Plant Explosion

    The firm successfully represented 270 plaintiffs, taking a lead role in the plaintiffs’ steering committee, who suffered injuries in a large plant explosion resulting in a settlement of nearly $80 million.

  • $50+ Million Plant Fire & Explosion

    The firm successfully represented 45 personal injury victims in a plant fire and explosion, serving on the plaintiffs steering committee, concluding with a settlement of more than $50 million.

  • $22+ Million Worksite Accident

    The firm prevailed in a personal injury trial for a worksite injury client with the jury returning a verdict and resulting in a judgment of over $22 million for the firm’s client.

  • $12 Million 18-Wheeler Collision

    The firm successfully achieved a $12 million settlement for the family of a man who died in an 18 wheeler collision.

  • $48 Million Catastrophic Burns

    The firm prevailed on behalf of three burn victims with settlements totaling nearly $48 million.

Our Record Of Success

When you are hurt and you choose a law firm to represent you in court or at the negotiation table, you need to carefully consider the firm's record.

Read More Success Stories

Let Us Help You Request a Free Consultation Today

Get Help Now

Bold labels are required.

Contact Information
disclaimer.

The use of the Internet or this form for communication with the firm or any individual member of the firm does not establish an attorney-client relationship. Confidential or time-sensitive information should not be sent through this form.

close

Privacy Policy

Back to top